Skip to main content

Table 2 Patient-Provider Communication Regarding Drug Costs

From: Patient-provider communication regarding drug costsin Medicare Part D beneficiaries with diabetes: a TRIAD Study

Patient/Plan Characteristics Thought issue of drug costs important enough to raise with MD (% strongly agree/agree) Wants MD to consider cost when choosing drugs (% yes) Talked with MD about amount paid for drugs (% yes) MD switched any drug to a less expensive version because of cost (% yes) Used any drug less often than prescribed because of cost (% yes)
Overall Sample (n = 1458) 76% 80% 44% 47% 22%
Adjusted Percents+      
Female 78% 84%* 47% 51% 25%*
Male++ 74% 78% 43% 44% 20%
White++ 76% 81% 48% 49% 23%
Non-White 77% 80% 37%*** 43% 23%
Age 65-74 81%*** 83% 50%** 45% 29%***
Age 75++ 70% 79% 41% 51% 16%
Income < $25 K 80%* 82% 51%*** 47% 27%***
Income $25-40 K 78% 84% 49%*** 57%* 24%***
Income > $40 K++ 72% 78% 37% 41% 17%
Integrated Delivery System MAPD++ 66% 77% 36% 33% 21%
For-Profit MAPD 81%*** 84%* 50%*** 53%*** 24%
For-Profit PDP 79%* 81% 51%** 57%** 26%
  1. *p < .05, ** p < .01, *** p < .001
  2. + From models adjusted for age, gender, income, education, comorbidities, race/ethnicity, difference between total and OOP costs in first quarter (Q1) of 2006, % generic medications in Q1 of 2006, and month of gap entry.
  3. ++Referent Group.